---
document_datetime: 2025-12-02 05:03:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tysabri.html
document_name: tysabri.html
version: success
processing_time: 0.177427
conversion_datetime: 2025-12-27 19:33:54.682481
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tysabri

[RSS](/en/individual-human-medicine.xml/66652)

##### Authorised

This medicine is authorised for use in the European Union

natalizumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tysabri](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77401)
- [More information on Tysabri](#more-information-on-tysabri-1385)
- [More information on Tysabri](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tysabri is a medicine for treating adults with multiple sclerosis (MS) that is not sufficiently controlled with another disease-modifying therapy or is rapidly getting worse.

Multiple sclerosis is a disease of the nerves, in which inflammation destroys the protective sheath surrounding nerves and damages the nerves themselves.

Tysabri is used in relapsing-remitting MS, a type of MS in which the patient has attacks (relapses) between periods of stable symptoms (remissions).

It contains the active substance natalizumab.

Expand section

Collapse section

## How is Tysabri used?

Treatment with Tysabri should be started and supervised by a doctor who is experienced in treating diseases of the nervous system and has access to a magnetic resonance imaging (MRI) scanner. This scanner will enable the doctor to check for changes in the brain or spinal cord linked to MS or to the brain infection called progressive multifocal leukoencephalopathy (PML), which has been associated with Tysabri and other MS medicines.

Tysabri is given as a 1-hour infusion (drip) into a vein once every 4 weeks. Because the infusion can trigger an allergic reaction, the patient must be monitored during the infusion and for 1 hour afterwards. If there is no clear benefit for the patient after 6 months, the doctor should re-assess the treatment.

The medicine can only be obtained with a prescription.

For more information about using Tysabri, see the package leaflet or contact your doctor or pharmacist.

## How does Tysabri work?

The active substance in Tysabri, natalizumab, is a monoclonal antibody which targets a protein called ?4?1 integrin on white blood cells involved in inflammation. By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting nerve damage. This helps to reduce symptoms of the disease.

## What benefits of Tysabri have been shown in studies?

Tysabri was effective at reducing the number of relapses and the worsening of disability (as measured with the Expanded Disability Status Scale).

In a study comparing Tysabri with placebo (a dummy treatment), the number of MS attacks in Tysabri-treated patients fell by about 68% after a year, compared with the patients who received placebo. In addition, the risk of disability getting worse was reduced by 42% over 2 years with Tysabri in comparison with placebo.

A second study showed that adding Tysabri to treatment with another medicine, interferon beta-1a, was more effective than adding placebo, reducing the risk of disability getting worse and the number of relapses. While the study showed that Tysabri was effective, it also raised concerns that combination with interferon beta-1a increased the risk of the serious brain infection PML.

Finally, a third study, still ongoing, has shown the average number of MS attacks per year falling from about 2 to 0.2 in Tysabri-treated patients (regardless of which disease-modifying treatment they had previously used). The response was maintained for up to 5 years.

## What are the risks associated with Tysabri?

Tysabri can increase the risk of infections, including the brain infection PML. PML is a very serious condition that may result in severe disability or death. The risk of PML increases the longer a patient has been receiving Tysabri, especially in patients treated for more than 2 years. The risk is also higher for patients who used medicines that supress the immune system before starting Tysabri, or if the patient has antibodies against the virus that causes PML. If PML is suspected, the doctor must stop treatment until it is certain that the patient does not have the infection.

The most common side effects with Tysabri (which may affect more than 1 in 10 people) are urinary tract infection, nasopharyngitis (inflammation of the nose and throat), headache, dizziness, nausea (feeling sick), joint pain and tiredness.

About 6% of the patients in studies developed long-lasting antibodies against natalizumab, which reduced the medicine's effectiveness.

Tysabri must not be given to patients who have PML or who are at risk of getting an infection, including patients whose immune system is weakened. It must not be given in combination with other disease-modifying medicines or to patients who have cancer (unless it is a skin cancer called basal cell carcinoma).

For the full list of side effects and restrictions of Tysabri, see the package leaflet.

## Why is Tysabri authorised in the EU?

Studies have shown that Tysabri is effective in treating relapsing-remitting MS. However, because of its safety risks, it should only be used in patients who have a real need for the medicine either because their disease is not sufficiently controlled with at least one other disease-modifying therapy or is rapidly getting worse.

The European Medicines Agency decided therefore that Tysabri's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tysabri?

The company that markets Tysabri has agreed on measures to improve the monitoring of patients with each Member State, such as registries and studies of patients receiving Tysabri. It will also supply all doctors who prescribe Tysabri with an educational pack that includes information on the safety of Tysabri, including information on which patients may be at a higher or lower risk of PML. Patients should receive this information when starting Tysabri, when continuing treatment for longer than 2 years, and when stopping treatment, as the risk of PML persists for 6 months after stopping treatment. The pack will also include information about other risks of this medicine for patients.

Patients who receive Tysabri must be given a special alert card that summarises the key safety information about the medicine. Patients should read this card carefully and keep it with them. Patients should make sure their partner or carer, as well as other doctors treating them, are aware of its content.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tysabri have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tysabri are continuously monitored. Side effects reported with Tysabri are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tysabri

Tysabri received a marketing authorisation valid throughout the EU on 27 June 2006.

Tysabri : EPAR - Medicine overview

English (EN) (135.59 KB - PDF)

**First published:** 18/06/2009

**Last updated:** 04/05/2020

[View](/en/documents/overview/tysabri-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-10)

български (BG) (148.94 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/bg/documents/overview/tysabri-epar-medicine-overview_bg.pdf)

español (ES) (130.78 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/es/documents/overview/tysabri-epar-medicine-overview_es.pdf)

čeština (CS) (147.56 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/cs/documents/overview/tysabri-epar-medicine-overview_cs.pdf)

dansk (DA) (130.28 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/da/documents/overview/tysabri-epar-medicine-overview_da.pdf)

Deutsch (DE) (133.77 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/de/documents/overview/tysabri-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.58 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/et/documents/overview/tysabri-epar-medicine-overview_et.pdf)

ελληνικά (EL) (149.91 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/el/documents/overview/tysabri-epar-medicine-overview_el.pdf)

français (FR) (134.51 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/fr/documents/overview/tysabri-epar-medicine-overview_fr.pdf)

hrvatski (HR) (147.14 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/hr/documents/overview/tysabri-epar-medicine-overview_hr.pdf)

italiano (IT) (130.35 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/it/documents/overview/tysabri-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (121.13 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/lv/documents/overview/tysabri-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (146.69 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/lt/documents/overview/tysabri-epar-medicine-overview_lt.pdf)

magyar (HU) (147.68 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/hu/documents/overview/tysabri-epar-medicine-overview_hu.pdf)

Malti (MT) (122.33 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/mt/documents/overview/tysabri-epar-medicine-overview_mt.pdf)

Nederlands (NL) (129.83 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/nl/documents/overview/tysabri-epar-medicine-overview_nl.pdf)

polski (PL) (148.2 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/pl/documents/overview/tysabri-epar-medicine-overview_pl.pdf)

português (PT) (130.87 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/pt/documents/overview/tysabri-epar-medicine-overview_pt.pdf)

română (RO) (144.96 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/ro/documents/overview/tysabri-epar-medicine-overview_ro.pdf)

slovenčina (SK) (147.74 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/sk/documents/overview/tysabri-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.89 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/sl/documents/overview/tysabri-epar-medicine-overview_sl.pdf)

Suomi (FI) (127.34 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/fi/documents/overview/tysabri-epar-medicine-overview_fi.pdf)

svenska (SV) (129.65 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

04/05/2020

[View](/sv/documents/overview/tysabri-epar-medicine-overview_sv.pdf)

Tysabri : EPAR - Risk-management-plan

English (EN) (512.45 KB - PDF)

**First published:** 21/02/2024

**Last updated:** 14/11/2025

[View](/en/documents/rmp/tysabri-epar-risk-management-plan_en.pdf)

## Product information

Tysabri : EPAR - Product information

English (EN) (1015.79 KB - PDF)

**First published:** 18/06/2009

**Last updated:** 25/11/2025

[View](/en/documents/product-information/tysabri-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-674)

български (BG) (1.16 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/bg/documents/product-information/tysabri-epar-product-information_bg.pdf)

español (ES) (1.04 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/es/documents/product-information/tysabri-epar-product-information_es.pdf)

čeština (CS) (1.17 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/cs/documents/product-information/tysabri-epar-product-information_cs.pdf)

dansk (DA) (1.03 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/da/documents/product-information/tysabri-epar-product-information_da.pdf)

Deutsch (DE) (1.06 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/de/documents/product-information/tysabri-epar-product-information_de.pdf)

eesti keel (ET) (1.06 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/et/documents/product-information/tysabri-epar-product-information_et.pdf)

ελληνικά (EL) (1.18 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/el/documents/product-information/tysabri-epar-product-information_el.pdf)

français (FR) (1.13 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/fr/documents/product-information/tysabri-epar-product-information_fr.pdf)

hrvatski (HR) (1.11 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/hr/documents/product-information/tysabri-epar-product-information_hr.pdf)

íslenska (IS) (1.02 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/is/documents/product-information/tysabri-epar-product-information_is.pdf)

italiano (IT) (1.05 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/it/documents/product-information/tysabri-epar-product-information_it.pdf)

latviešu valoda (LV) (1.09 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/lv/documents/product-information/tysabri-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.13 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/lt/documents/product-information/tysabri-epar-product-information_lt.pdf)

magyar (HU) (1.1 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/hu/documents/product-information/tysabri-epar-product-information_hu.pdf)

Malti (MT) (1.28 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/mt/documents/product-information/tysabri-epar-product-information_mt.pdf)

Nederlands (NL) (1.11 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/nl/documents/product-information/tysabri-epar-product-information_nl.pdf)

norsk (NO) (1 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/no/documents/product-information/tysabri-epar-product-information_no.pdf)

polski (PL) (1.11 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/pl/documents/product-information/tysabri-epar-product-information_pl.pdf)

português (PT) (1.04 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/pt/documents/product-information/tysabri-epar-product-information_pt.pdf)

română (RO) (1.08 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/ro/documents/product-information/tysabri-epar-product-information_ro.pdf)

slovenčina (SK) (1.12 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/sk/documents/product-information/tysabri-epar-product-information_sk.pdf)

slovenščina (SL) (1.03 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/sl/documents/product-information/tysabri-epar-product-information_sl.pdf)

Suomi (FI) (1.06 MB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/fi/documents/product-information/tysabri-epar-product-information_fi.pdf)

svenska (SV) (1022.86 KB - PDF)

**First published:**

18/06/2009

**Last updated:**

25/11/2025

[View](/sv/documents/product-information/tysabri-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000314074 25/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tysabri : EPAR - All authorised presentations

English (EN) (80.35 KB - PDF)

**First published:** 09/11/2007

**Last updated:** 06/04/2021

[View](/en/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-593)

български (BG) (96.01 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/bg/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_bg.pdf)

español (ES) (79.49 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/es/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_es.pdf)

čeština (CS) (88.68 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/cs/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (76.31 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/da/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (107 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/de/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (78.4 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/et/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (94.3 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/el/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_el.pdf)

français (FR) (80.21 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/fr/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (131.83 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/hr/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (104.08 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/is/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_is.pdf)

italiano (IT) (78.92 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/it/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (97.73 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/lv/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (98.7 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/lt/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (95.36 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/hu/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (123.76 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/mt/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (74.63 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/nl/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (80.95 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/no/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_no.pdf)

polski (PL) (128.16 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/pl/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_pl.pdf)

português (PT) (78.14 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/pt/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_pt.pdf)

română (RO) (123.06 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/ro/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (123.3 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/sk/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (107.41 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/sl/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (102.51 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/fi/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (80.06 KB - PDF)

**First published:**

09/11/2007

**Last updated:**

06/04/2021

[View](/sv/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_sv.pdf)

Tysabri : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (43.8 KB - PDF)

**First published:** 31/05/2007

**Last updated:** 08/07/2011

[View](/en/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (23)](#file-language-dropdown-59)

български (BG) (146.24 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/bg/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (94.75 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/es/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (129.15 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/cs/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (97.4 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/da/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (34.99 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/de/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (33.93 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/et/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (201.72 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/el/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (32.69 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/fr/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

íslenska (IS) (62.24 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/is/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_is.pdf)

italiano (IT) (34.25 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/it/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (126.71 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/lv/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (132.36 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/lt/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (97.93 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/hu/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (130.18 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/mt/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (26.05 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/nl/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

norsk (NO) (36.75 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/no/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_no.pdf)

polski (PL) (134.09 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/pl/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (34.82 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/pt/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (130.19 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/ro/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (134.95 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/sk/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (163.84 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/sl/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (95.74 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/fi/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (94.46 KB - PDF)

**First published:**

31/05/2007

**Last updated:**

08/07/2011

[View](/sv/documents/conditions-member-states/tysabri-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Tysabri Active substance natalizumab International non-proprietary name (INN) or common name natalizumab Therapeutic area (MeSH) Multiple Sclerosis Anatomical therapeutic chemical (ATC) code L04AG03

### Pharmacotherapeutic group

Monoclonal antibodies

### Therapeutic indication

Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:

- Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or
- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

## Authorisation details

EMA product number EMEA/H/C/000603 Marketing authorisation holder

Biogen Netherlands B.V.

Prins Mauritslaan 13 1171 LP Badhoevedorp The Netherlands

Marketing authorisation issued 27/06/2006 Revision 50

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tysabri : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (161.88 KB - PDF)

**First published:** 14/11/2025

**Last updated:** 25/11/2025

[View](/en/documents/procedural-steps-after/tysabri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tysabri : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (411.46 KB - PDF)

**First published:** 18/06/2009

**Last updated:** 14/11/2025

[View](/en/documents/procedural-steps-after/tysabri-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tysabri-H-C-PSUSA-00002127-202108 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/561269/2022

English (EN) (126.92 KB - PDF)

**First published:** 08/06/2022

[View](/en/documents/scientific-conclusion/tysabri-h-c-psusa-00002127-202108-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tysabri-H-C-PSUSA-00002127-202008 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/158932/2021

English (EN) (96.16 KB - PDF)

**First published:** 15/06/2021

[View](/en/documents/scientific-conclusion/tysabri-h-c-psusa-00002127-202008-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tysabri-H-C-603-X-0116 : EPAR - Assessment report - Extension

Adopted

Reference Number: EMA/CHMP/102816/2021

English (EN) (1.71 MB - PDF)

**First published:** 06/04/2021

[View](/en/documents/variation-report/tysabri-h-c-603-x-0116-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Tysabri (X-116)

Adopted

Reference Number: EMA/CHMP/50871/2021

English (EN) (131.35 KB - PDF)

**First published:** 01/02/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri-x-116_en.pdf)

Tysabri-H-C-PSUSA-00002127-201908 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/160227/2020

English (EN) (132.93 KB - PDF)

**First published:** 04/05/2020

[View](/en/documents/scientific-conclusion/tysabri-h-c-psusa-00002127-201908-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tysabri-H-C-603-II-77 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/579064/2016

English (EN) (2.48 MB - PDF)

**First published:** 07/09/2016

**Last updated:** 07/09/2016

[View](/en/documents/variation-report/tysabri-h-c-603-ii-77-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tysabri

Adopted

Reference Number: EMA/CHMP/181854/2016

English (EN) (121.79 KB - PDF)

**First published:** 27/05/2016

**Last updated:** 27/05/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri_en.pdf)

Tysabri : EPAR - Scientific Conclusion

English (EN) (72.27 KB - PDF)

**First published:** 12/05/2016

**Last updated:** 12/05/2016

[View](/en/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_en.pdf)

[Other languages (22)](#file-language-dropdown-687)

български (BG) (100.06 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/bg/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_bg.pdf)

español (ES) (73.9 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/es/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_es.pdf)

čeština (CS) (93.86 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/cs/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_cs.pdf)

dansk (DA) (72.2 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/da/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_da.pdf)

Deutsch (DE) (70.07 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/de/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_de.pdf)

eesti keel (ET) (69.43 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/et/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_et.pdf)

ελληνικά (EL) (119.04 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/el/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_el.pdf)

français (FR) (72.68 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/fr/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_fr.pdf)

hrvatski (HR) (109.16 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/hr/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_hr.pdf)

italiano (IT) (69.5 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/it/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_it.pdf)

latviešu valoda (LV) (112.38 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/lv/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_lv.pdf)

lietuvių kalba (LT) (109.25 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/lt/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_lt.pdf)

magyar (HU) (93.66 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/hu/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_hu.pdf)

Malti (MT) (119.22 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/mt/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_mt.pdf)

Nederlands (NL) (70.67 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/nl/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_nl.pdf)

polski (PL) (98.26 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/pl/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_pl.pdf)

português (PT) (74.99 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/pt/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_pt.pdf)

română (RO) (130.53 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/ro/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_ro.pdf)

slovenčina (SK) (93.91 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/sk/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_sk.pdf)

slovenščina (SL) (91.56 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/sl/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_sl.pdf)

Suomi (FI) (66.64 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/fi/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_fi.pdf)

svenska (SV) (70.69 KB - PDF)

**First published:**

12/05/2016

**Last updated:**

12/05/2016

[View](/sv/documents/scientific-conclusion/tysabri-epar-scientific-conclusion_sv.pdf)

Tysabri-H-C-603-A20-1416 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/PRAC/171485/2016

English (EN) (1.4 MB - PDF)

**First published:** 12/05/2016

**Last updated:** 12/05/2016

[View](/en/documents/variation-report/tysabri-h-c-603-a20-1416-epar-assessment-report-article-20_en.pdf)

Tysabri-H-C-603-PSUV-0062 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/178698/2014

English (EN) (72.55 KB - PDF)

**First published:** 01/04/2014

**Last updated:** 01/04/2014

[View](/en/documents/scientific-conclusion/tysabri-h-c-603-psuv-0062-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Tysabri-H-C-603-II-0059-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/297726/2013

English (EN) (738.39 KB - PDF)

**First published:** 20/08/2013

**Last updated:** 20/08/2013

[View](/en/documents/variation-report/tysabri-h-c-603-ii-0059-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tysabri

Reference Number: EMA/321062/2013

English (EN) (68.45 KB - PDF)

**First published:** 31/05/2013

**Last updated:** 31/05/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri_en.pdf-0)

Tysabri-H-C-603-A20-0029: EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/430923/2010

English (EN) (114.16 KB - PDF)

**First published:** 19/08/2010

**Last updated:** 19/08/2010

[View](/en/documents/variation-report/tysabri-h-c-603-a20-0029-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Tysabri : EPAR - Scientific Discussion

English (EN) (243.79 KB - PDF)

**First published:** 31/05/2007

**Last updated:** 31/05/2007

[View](/en/documents/scientific-discussion/tysabri-epar-scientific-discussion_en.pdf)

Tysabri : EPAR - Procedural steps taken before authorisation

English (EN) (198.25 KB - PDF)

**First published:** 31/05/2007

**Last updated:** 04/05/2020

[View](/en/documents/procedural-steps/tysabri-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Tysabri

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-may-2016) 27/05/2016

[EMA confirms recommendations to minimise risk of brain infection PML with Tysabri](/en/news/ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri) 26/02/2016

[Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri](/en/news/updated-recommendations-minimise-risk-rare-brain-infection-pml-tysabri) 12/02/2016

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 May 2015](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-may-2015) 08/05/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2013) 31/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 18-21 January 2010](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-january-2010) 28/01/2010

[European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy (PML) with Tysabri](/en/news/european-medicines-agency-recommends-additional-measures-better-manage-risk-progressive-multifocal-leukoencephalopathy-pml-tysabri) 21/01/2010

[European Medicines Agency recommends update of product information of Tysabri and risk of progressive multifocal leukoencephalopathy (PML)](/en/news/european-medicines-agency-recommends-update-product-information-tysabri-risk-progressive-multifocal-leukoencephalopathy-pml) 25/09/2008

[European Medicines Agency update on progressive multifocal leukoencephalopathy (PML) and Tysabri](/en/news/european-medicines-agency-update-progressive-multifocal-leukoencephalopathy-pml-tysabri) 13/08/2008

[European Medicines Agency concludes new advice to doctors and patients for Tysabri (natalizumab) needed](/en/news/european-medicines-agency-concludes-new-advice-doctors-patients-tysabri-natalizumab-needed) 20/03/2008

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Tysabri : EPAR - Product information - tracked changes

English (EN) (1.34 MB - DOCX)

**First published:** 19/06/2025

**Last updated:** 25/11/2025

[View](/en/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-503)

български (BG) (876.28 KB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/bg/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_bg.docx)

español (ES) (1.34 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/es/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_es.docx)

čeština (CS) (1.33 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/cs/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (1.29 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/da/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (1.34 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/de/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (1.34 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/et/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (1.36 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/el/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_el.docx)

français (FR) (1.33 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/fr/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (1.3 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/hr/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (1.36 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/is/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_is.docx)

italiano (IT) (826.01 KB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/it/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (1.31 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/lv/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (797.02 KB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/lt/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (806.75 KB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/hu/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (1.33 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/mt/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (1.31 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/nl/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (1.32 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/no/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_no.docx)

polski (PL) (1.33 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/pl/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_pl.docx)

português (PT) (826.36 KB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/pt/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_pt.docx)

română (RO) (1.31 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/ro/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (1.34 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/sk/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (1.3 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/sl/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (1.3 MB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/fi/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (784.29 KB - DOCX)

**First published:**

19/06/2025

**Last updated:**

25/11/2025

[View](/sv/documents/product-information-tracked-changes/tysabri-epar-product-information-tracked-changes_sv.docx)

#### More information on Tysabri

Questions and answers on the review of Tysabri (natalizumab)

Reference Number: EMA/27573/2010

English (EN) (65.06 KB - PDF)

**First published:** 21/01/2010

**Last updated:** 21/01/2010

[View](/en/documents/medicine-qa/questions-and-answers-review-tysabri-natalizumab_en.pdf)

#### More information on Tysabri

- [EMEA-001095-PIP02-12 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001095-pip02-12)
- [Tysabri - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/tysabri)
- [Tysabri - referral](/en/medicines/human/referrals/tysabri)
- [EMEA-001095-PIP03-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001095-pip03-19)
- [An Observational Study Utilising Data from EU National MS Registries to Estimate the Incidence of Anti-Natalizumab Antibody Among Patients Who Receive Subcutaneous Administration of Natalizumab for Treatment of RRMS - post-authorisation study](https://catalogues.ema.europa.eu/study/105827)
- [TOP: Tysabri® Observational Program - post-authorisation study](https://catalogues.ema.europa.eu/study/46161)
- [An observational study utilising data from the US Tysabri TOUCH programme and select EU MS Registries to estimate the risk of progressive multifocal leukoencephalopathy (PML) and other serious opportunistic infections among patients who were exposed to an MS disease modifying treatment prior to treatment with Tysabri - post-authorisation study](https://catalogues.ema.europa.eu/study/48270)
- [An Observational, Cross-Sectional Survey to Assess PML Risk Awareness and Understanding from Patients' Perspective and Effectiveness of the Tysabri (Natalizumab) Patient Alert Card in the UK (T-PAC) - post-authorisation study](https://catalogues.ema.europa.eu/study/106698)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/11/2025

## Share this page

[Back to top](#main-content)